{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-1/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"c85ea3eb-a714-591e-9173-893969e82b38","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 9d4c48fe-1f2a-4d8c-9ec6-4901eb21b2d0 --><h2>Update</h2><!-- end field 9d4c48fe-1f2a-4d8c-9ec6-4901eb21b2d0 -->","summary":null,"htmlStringContent":"<!-- begin item 71f19ea7-40cd-419e-82bc-da94f42d45cb --><!-- end item 71f19ea7-40cd-419e-82bc-da94f42d45cb -->","topic":{"id":"e0026a38-6f9d-5508-9a1c-f9cb4d041950","topicId":"83d7e1f3-89ef-4bb8-9e6c-8f19b4d34e87","topicName":"Diabetes - type 1","slug":"diabetes-type-1","lastRevised":"Last revised in November 2020","chapters":[{"id":"d661aaf0-a104-5e58-84d5-4a2a8a0f4f5d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4c43c028-bb33-5fef-9faa-b1109c46c86c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0b467f1-8df4-5e16-b575-6586d482ff25","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3b6f1413-616a-5f8a-bdb2-5039d4c9da3d","slug":"changes","fullItemName":"Changes"},{"id":"c85ea3eb-a714-591e-9173-893969e82b38","slug":"update","fullItemName":"Update"}]},{"id":"5c1743f6-3cac-5ff9-adaf-cb4e0825d600","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"87ced251-ae95-56bb-af77-2ff4fed8e622","slug":"goals","fullItemName":"Goals"},{"id":"65dfcd12-0085-5a25-bb44-e3c6fc31638d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5062125f-ab58-5026-aaff-b6b85d231c1c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8599fb5-b011-56d3-a366-6cf800a0fefa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8c093980-e55d-5ca2-b0b5-b2f4510c1c97","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9c0a7c64-7734-5a4a-83ed-b90c2c0bbe1c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d65f3cd5-05c6-5a1e-9944-451040c15857","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d43fa19c-c0e0-573b-b397-39d8c6688f93","slug":"definition","fullItemName":"Definition"},{"id":"8a652055-2d88-550f-8db1-ae8e33b071bd","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"90b285f5-e373-561a-826a-e61feb7838dd","slug":"incidence-prevalence","fullItemName":"Incidence and prevalence"},{"id":"9cae1d9c-e58a-549e-90b2-2d2cadc11677","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6923a3e8-0ad7-53c5-995c-b35c22158c20","slug":"complications","fullItemName":"Complications"}]},{"id":"a8fd4233-8b09-576a-b7a0-7f8ceeb4bdc8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4f5a4b78-cd62-5755-89da-ec0cde4a8f1b","slug":"diagnosis-adults","fullItemName":"Diagnosis - adults"},{"id":"6f5d18f4-c26e-5580-956a-03c18359bca5","slug":"diagnosis-children-young-people","fullItemName":"Diagnosis - children and young people"},{"id":"325f4df9-1bb2-5a87-a070-e07935161353","slug":"when-to-suspect-diabetic-ketoacidosis","fullItemName":"When to suspect diabetic ketoacidosis"},{"id":"2a892a37-ec75-5c0c-b79d-9b550ba6f44a","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"ef2fcfd0-0be0-5051-a142-f33f073f8866","fullItemName":"Management","slug":"management","subChapters":[{"id":"18ccffe2-a6f3-577e-91e5-cb4155aa3217","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"e6d0bbff-43a3-5fba-bff0-2be7be288c52","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"23697cf0-b89b-5f73-af63-48585cfa9295","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"15bdab2b-50dc-5e17-9f62-653119d307ca","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bc8c7324-ac1b-5655-93c6-4b5346239433","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1558081d-ff31-5041-982a-0995ddcdac09","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6ce82109-660d-58c4-8f94-f3daf311c5a8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59ae6a38-016e-5016-8cee-931384eb78b4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"03942c19-0b79-5891-a48e-fc314241de96","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f415e38-eb27-5fde-8084-57d74c402a7c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e0b467f1-8df4-5e16-b575-6586d482ff25","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"764fc811-2609-5562-89a2-098c6b084b64","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field c020ff73-e719-402c-9c83-223f2169bc7e --><h3>New evidence</h3><!-- end field c020ff73-e719-402c-9c83-223f2169bc7e -->","summary":null,"htmlStringContent":"<!-- begin item eb7e236b-5da1-4677-8ca4-331183845572 --><!-- begin field 558cffcd-4e26-4869-ae5f-3b929a4c2a00 --><h3>Evidence-based guidelines</h3><!-- end field 558cffcd-4e26-4869-ae5f-3b929a4c2a00 --><!-- begin field 8b524db1-5dbc-4acd-acf0-4df2af3c1572 --><ul><li>Navaneethan, S.D., Zoungas, S., Caramori, M.L., et al. (2020) <em>Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline.</em> Annals of Internal Medicine. <a href=\"https://www.acpjournals.org/\" data-hyperlink-id=\"344082c4-9770-4995-9e31-ac75010517ea\">www.acpjournals.org</a> [<a href=\"https://www.acpjournals.org/doi/10.7326/M20-5938\" data-hyperlink-id=\"0a6d54ca-c850-4f03-a3c2-ac7501051a26\">Free Full-text</a>]</li></ul><!-- end field 8b524db1-5dbc-4acd-acf0-4df2af3c1572 --><!-- begin field 0db28f9a-8be8-418d-802d-b597beaff0d6 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 0db28f9a-8be8-418d-802d-b597beaff0d6 --><!-- begin field f4a09d66-ca1e-4a8d-8656-a558ab828ed3 --><p>No new HTAs since 1 July 2020.</p><!-- end field f4a09d66-ca1e-4a8d-8656-a558ab828ed3 --><!-- begin field 3fba4ca2-7207-42a8-bab8-df5b31ad8a1a --><h3>Economic Appraisals</h3><!-- end field 3fba4ca2-7207-42a8-bab8-df5b31ad8a1a --><!-- begin field 4ee9fee4-256f-4b6f-8593-892eea0be7b7 --><p>No new economic appraisals relevant to England since 1 July 2020.</p><!-- end field 4ee9fee4-256f-4b6f-8593-892eea0be7b7 --><!-- begin field bc67a0e0-fda7-4b06-94d3-41398404e799 --><h3>Systematic reviews and meta-analyses</h3><!-- end field bc67a0e0-fda7-4b06-94d3-41398404e799 --><!-- begin field 8381bea9-c367-48fc-ae75-bae797571d5d --><ul><li>No new systematic reviews or meta-analyses since 1 July 2020.</li></ul><!-- end field 8381bea9-c367-48fc-ae75-bae797571d5d --><!-- begin field 2202364d-d36d-4344-9acd-fbdc407d7ca2 --><h3>Primary evidence</h3><!-- end field 2202364d-d36d-4344-9acd-fbdc407d7ca2 --><!-- begin field 182d66f5-1f96-4882-a9c2-2e36cadcb3d9 --><ul><li>Charleer, S., De Block, C., Nobels, F., et al. (2020)<em> Sustained impact of real-time continuous glucose monitoring in adults with type 1 diabetes on insulin pump therapy: results after the 24-month RESCUE study. </em>Diabetes Care. <a href=\"https://care.diabetesjournals.org/\" data-hyperlink-id=\"aaa867cb-2ea4-48fe-920a-ac5d009a1ac3\">www.care.diabetesjournals.org</a> [<a href=\"https://care.diabetesjournals.org/content/early/2020/10/11/dc20-1531\" data-hyperlink-id=\"efbd4435-2aaf-4801-b9ca-ac5d009a1b50\">Abstract</a>]Â </li><li>Haskova, A., Radovnicka, L., Petruzelkova, L., et al. (2020) <em>Real-time CGM is superior to flash glucose monitoring for glucose control in type 1 diabetes: the CORRIDA randomized controlled trial.</em> Diabetes Care. <a href=\"https://care.diabetesjournals.org/\" data-hyperlink-id=\"4f5da8fe-3a1c-4024-be2d-ac5d009a1ca5\">www.care.diabetesjournals.org</a> [<a href=\"https://care.diabetesjournals.org/content/43/11/2744\" data-hyperlink-id=\"bcaf05ff-ae2a-48b8-b18a-ac5d009a1d1f\">Free Full-text</a>]</li><li>Murphy, H.R., Howgate, C., O'Keefe, J., et al. (2021) <em>Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study</em>. Lancet Diabetes & Endocrinology. <a href=\"https://www.thelancet.com/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"aa4f90f5-a49a-4f68-9c12-acc600b6f096\">www.thelancet.com</a> [<a href=\"https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30406-X/fulltext\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"0062e487-93d8-41de-8e1c-acc600b6f096\">Abstract</a>]</li></ul><!-- end field 182d66f5-1f96-4882-a9c2-2e36cadcb3d9 --><!-- end item eb7e236b-5da1-4677-8ca4-331183845572 -->","subChapters":[]},{"id":"8ef095b0-7016-52bd-a629-94992c2df699","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field ffc8f9bc-c1ab-4504-8086-cde6b09cf557 --><h3>New policies</h3><!-- end field ffc8f9bc-c1ab-4504-8086-cde6b09cf557 -->","summary":null,"htmlStringContent":"<!-- begin item 28740b98-bc51-4b0e-82e2-68c8d9e2f833 --><!-- begin field 2d7a4ff9-56fd-414f-ab97-b86eda4d2280 --><p>No new national policies or guidelines since 1 July 2020.</p><!-- end field 2d7a4ff9-56fd-414f-ab97-b86eda4d2280 --><!-- end item 28740b98-bc51-4b0e-82e2-68c8d9e2f833 -->","subChapters":[]},{"id":"908352da-28dc-5988-a1bb-3b3066eb16b2","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field c2b85038-2bbb-40d6-8c9c-b9c2b0d69585 --><h3>New safety alerts</h3><!-- end field c2b85038-2bbb-40d6-8c9c-b9c2b0d69585 -->","summary":null,"htmlStringContent":"<!-- begin item 4a251a7e-d3e8-419e-84ba-96188e2dbdaf --><!-- begin field deea529d-66d0-4ec1-80db-021024c50a31 --><p>No new safety alerts since 1 July 2020.</p><!-- end field deea529d-66d0-4ec1-80db-021024c50a31 --><!-- end item 4a251a7e-d3e8-419e-84ba-96188e2dbdaf -->","subChapters":[]},{"id":"a8f04715-42f4-5530-9a13-fd3532cd3f03","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 320879f0-3d08-4adf-8c30-da2585e5ff68 --><h3>Changes in product availability</h3><!-- end field 320879f0-3d08-4adf-8c30-da2585e5ff68 -->","summary":null,"htmlStringContent":"<!-- begin item 3522546b-ed3c-4254-86f5-c41f10624ad0 --><!-- begin field 5304f684-ff80-4ac2-abbb-96fffb154928 --><ul><li>Ogluo is a hybrid of GlucaGen/GlucaGen Hypokit but is available as a ready-to-use formulation intended for subcutaneous injection and indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. See more <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/ogluo\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"a3ff0910-3081-46e4-bd1d-ac9500b559cc\">here</a>.</li><li>Kixelle has comparable quality, safety, and efficacy to the reference product NovoRapid and is indicated for treatment of diabetes mellitus in adults, adolescents, and children aged 1 year and above. See more <a href=\"https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kixelle\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"9b206a70-3d2b-4865-8cd9-ac9500b62d3c\">here</a>.</li></ul><!-- end field 5304f684-ff80-4ac2-abbb-96fffb154928 --><!-- end item 3522546b-ed3c-4254-86f5-c41f10624ad0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}